Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBluecross Idaho Tepezza Coverage Update | OpenPaye…
    Ask Trek AI about this page
    ModifiedBluecross IdahoPolicy MP 5.01.660

    Tepezza (teprotumumab-trbw) Coverage Criteria for Thyroid Eye Disease

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy MP 5.01.660 alerts

    Get alerted when Policy MP 5.01.660 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical-necessity coverage and authorization criteria for intravenous Tepezza in adults with moderate-to-severe thyroid eye disease associated with Graves' disease.

    Policy Summary
    PayerBluecross Idaho
    PolicyTepezza (teprotumumab-trbw) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 1, 202744d
    Last ReviewSep 24, 2026
    Next Review DateN/A
    Key ActionDocument the patient's age, specialist involvement, Graves' disease, thyroid eye disease findings, thyroid laboratory results, and applicable treatment rationale.
    SourceLink
    POLICY UPDATE CHANGES

    Clinical Activity Score reporting was removed from the policy requirements.

    Statements about systemic corticosteroid therapy were clarified.

    The policy statements were updated as part of the policy revision.

    18+Minimum age for initial treatment
    8 infusionsMaximum treatment course
    10→20 mg/kgInitial and subsequent dosing
    ≥3

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CAS threshold for incomplete course
    6 monthsPost-treatment contraception

    Coverage Criteria

    Initial Therapy

    Tepezza may be considered medically necessary when all of the following are met.

    Initial Tepezza eligibility

    • ALL of the following

      • The individual is 18 years of age or older.
      • Tepezza is prescribed by or in consultation with an ophthalmologist, endocrinologist, or physician who specializes in thyroid eye disease.
      • The individual has a confirmed diagnosis of Graves' disease, such as Graves' ophthalmopathy or orbitopathy.
      • The individual has moderate-to-severe, active or inactive thyroid eye disease (TED).
      • At least one qualifying ocular finding

        • Lid retraction greater than 2 mm.
        • Moderate or severe soft-tissue involvement.
        • Proptosis greater than 3 mm above normal values for race and sex.
        • Periodic or constant diplopia.
      • The individual is euthyroid or mildly hyperthyroid or hypothyroid before starting Tepezza therapy.Free T4 and free T3 levels within 50% of normal limits for age and gender; for individuals age 20 years or older, free T4 0.9–1.7 ng/dL and free T3 2.8–4.4 pg/mL.
      • One clinical-rationale pathway

        • Significant proptosis or diplopia is present.
        • The individual has had an inadequate response, serious adverse effects, or a contraindication to 8 weeks of systemic corticosteroid therapy up to maximally indicated doses.

    Completion of Incomplete Course

    Medical necessity may be considered for the remaining doses when an individual started therapy but has not completed 8 doses.

    Completion of incomplete course

    • The individual has received fewer than 8 doses of Tepezza.
    • The individual retains an active diagnosis of thyroid eye disease (TED).
    • The individual has a Clinical Activity Score of at least 3 warranting treatment.CAS ≥3
    • Coverage is requested only for the number of doses required to receive a total of 8 doses.

      Repeat treatment after completion of one 8-dose course is considered investigational.

    Repeat treatment with Tepezza after completion of one full 8-infusion course is considered investigational because clinical trials have not demonstrated consistent clinical benefit beyond one course.

    Tepezza treatment is excluded when the individual currently requires orbital surgery or is undergoing, or planning, corrective surgery or irradiation during therapy.

    Tepezza treatment is excluded during pregnancy or when pregnancy is planned. Appropriate contraception should be used before treatment, during therapy, and for 6 months after the last dose.

    Treatment is excluded when the requested dosage exceeds the FDA-approved regimen of one 10 mg/kg initial dose followed by up to seven 20 mg/kg infusions every three weeks over six months.

    Requests are not medically necessary when the individual has previously completed one 8-dose course, has a concurrent orbital surgery or irradiation circumstance, is pregnant or plans to become pregnant, receives dosing above the FDA-approved regimen, does not meet the stated medical-necessity criteria, or seeks treatment for another indication.

    Coding and Clinical Thresholds

    HCPCSHCPCS
    C9061Injection, teprotumumab-trbw, 10 mg (Tepezza)
    C9399Unclassified drugs or biologicals.
    J3490Unclassified drugs.
    ICD 10ICD-10
    E05.00Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm
    Lid Retraction
    Qualifying measurementLid retraction greater than 2 mm
    Clinical contextA qualifying ocular finding for moderate-to-severe thyroid eye disease
    RequirementAt least one qualifying ocular finding is required for initial Tepezza therapy
    Proptosis
    Qualifying measurementProptosis greater than 3 mm above normal values or the upper limit of normal for race and sex
    Clinical contextA qualifying ocular finding in moderate-to-severe thyroid eye disease

    Provider Documentation and Denial Risks

    Documentation Required

    Systemic Corticosteroid History

    Before requesting Tepezza for an individual without significant proptosis or diplopia, document an inadequate response, serious adverse effects, or contraindication after 8 weeks of systemic corticosteroid therapy at maximally indicated doses.

    • Document the corticosteroid agent, dose, duration, response, and reason therapy was ineffective, not tolerated, or contraindicated.
    • Examples include prednisone 30 mg/day orally or methylprednisolone 500 mg IV once weekly for weeks 1–6, followed by 250 mg IV once weekly.
    Documentation Required

    Initial-Treatment Clinical Documentation

    For initial treatment, submit documentation showing that all medical-necessity criteria are satisfied and identify the treating or consulting qualified specialist.

    • Individual is age 18 or older.
    • Tepezza is prescribed by or in consultation with an ophthalmologist, endocrinologist, or physician specializing in thyroid eye disease.

    Background

    Thyroid eye disease (TED), also called Graves' orbitopathy, is an inflammatory condition associated with Graves' disease. Inflammation and tissue expansion behind the eye may cause proptosis, pain, diplopia, disfigurement, or, in severe cases, blindness.

    Definitions

    Clinical Activity Score (CAS)
    DefinitionClinical Activity Score (CAS) measures activity of thyroid-associated ophthalmopathy
    Score range0 to 7
    Active disease thresholdA score of at least 3 indicates active thyroid-associated ophthalmopathy
    Thyroid Eye Disease (TED)
    Also calledGraves' ophthalmopathy or Graves' orbitopathy
    DefinitionAn inflammatory disease associated with Graves' disease
    Potential manifestationsMay cause proptosis, diplopia, and eyelid or soft-tissue changes

    Initial Therapy Criteria

    Initial Therapy

    Initial Tepezza therapy may be considered medically necessary when all of the following requirements are met.

    Initial Tepezza eligibility

    • ALL of the following

      • The individual is 18 years of age or older.
      • Tepezza is prescribed by or in consultation with an ophthalmologist, endocrinologist, or physician who specializes in thyroid eye disease.
      • The individual has a confirmed diagnosis of Graves' disease, such as Graves' ophthalmopathy or orbitopathy.
      • The individual has moderate-to-severe, active or inactive thyroid eye disease (TED).

    Continuation Criteria

    Continuation to Complete Initial Course

    For an individual who started Tepezza but has not completed 8 doses, coverage may be considered for the remaining doses when all criteria are met.

    Continuation to complete initial course

    • The individual has received fewer than 8 doses of Tepezza.
    • The individual retains an active diagnosis of thyroid eye disease (TED).
    • The individual has a Clinical Activity Score of at least 3 warranting treatment.CAS ≥3
    • Coverage is requested only for the number of doses required to receive a total of 8 doses.

      Repeat treatment after completion of one 8-dose course is considered investigational.

    Step-Therapy Requirements

    StepWhen applicableRequirement
    1When significant proptosis or diplopia is not presentDocument an inadequate response, serious adverse effects, or contraindication to 8 weeks of systemic corticosteroid therapy up to maximally indicated doses.

    Quantity Limits

    Tepezza (teprotumumab-trbw)
    Initial infusionOne 10 mg/kg intravenous infusion
    Subsequent infusionsUp to seven 20 mg/kg intravenous infusions every 3 weeks
    Maximum courseOne course of 8 infusions
    Policy Summary
    PayerBluecross Idaho
    PolicyTepezza (teprotumumab-trbw) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJan 1, 202744d
    Last ReviewSep 24, 2026
    Next Review DateN/A
    Key ActionDocument the patient's age, specialist involvement, Graves' disease, thyroid eye disease findings, thyroid laboratory results, and applicable treatment rationale.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Documentation and Denial RisksBackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaStep-Therapy RequirementsQuantity Limits
    Disease severity context
    Moderate-to-severe disease may include proptosis greater than 3 mm above the upper limit of normal for race
    Thyroid Laboratory Values
    Required thyroid statusFree T4 and free T3 within 50% of normal limits for age and gender
    Free T4 for age ≥20 years0.9–1.7 ng/dL
    Free T3 for age ≥20 years2.8–4.4 pg/mL
    Clinical Activity Score
    Score range0 to 7
    Active disease thresholdClinical Activity Score of at least 3
    Continuation requirementA CAS of at least 3 must warrant treatment when completing an incomplete course
    Proptosis Response in Clinical Studies
    Study response measureReduction in proptosis of at least 2 mm
    Assessment time pointWeek 24
    Clinical study contextMeaningful improvement in proptosis was evaluated without deterioration in the fellow eye
  1. Confirmed Graves' disease, such as Graves' ophthalmopathy or orbitopathy.
  2. Moderate-to-severe active or inactive TED with at least one of the following: lid retraction greater than 2 mm, moderate or severe soft-tissue involvement, proptosis greater than 3 mm above normal for race and sex, or periodic or constant diplopia.
  3. Thyroid status before treatment: euthyroid or mildly hyperthyroid/hypothyroid, with free T4 and T3 within 50% of normal limits for age and gender.
  4. Treatment history supporting either significant proptosis or diplopia, or the systemic corticosteroid history described above.
  5. Documentation Required

    Incomplete-Course Documentation

    For a patient who started Tepezza but did not complete the initial course, request only the doses needed to reach a total of 8 doses and document that active TED still warrants treatment.

    • Document the number of Tepezza doses already received and the number requested to complete 8 total doses.
    • Document continued active Thyroid Eye Disease and a Clinical Activity Score (CAS) of at least 3.
    Documentation Required

    Pregnancy and Contraception Documentation

    Before initiation, document pregnancy status, treatment planning, and counseling regarding fetal risk and contraception requirements.

    • Document that the patient is not pregnant and is not planning pregnancy during treatment.
    • Document effective contraception before initiation, throughout treatment, and for 6 months after the last dose.
    • Document treatment planning and counseling about discontinuation and fetal-risk counseling if pregnancy occurs during therapy.
    Denial Risk

    Repeat Treatment After 8 Doses

    Coverage is at risk when Tepezza is requested after a completed initial course because repeat treatment is considered investigational.

    • A completed course consists of 8 infusions.
    • Clinical trials have not demonstrated consistent clinical benefit beyond one course.
    Denial Risk

    Concurrent Orbital Treatment

    Coverage is at risk when the individual currently requires orbital surgery or is undergoing or planning corrective orbital surgery or irradiation during Tepezza therapy.

    • Document the status of any current or planned orbital surgery, corrective surgery, or irradiation.
    Denial Risk

    Pregnancy

    Tepezza should not be used during pregnancy or when pregnancy is planned because it may cause fetal harm and increase the risk of fetal loss.

    • Do not initiate or continue treatment during pregnancy.
    • Do not approve treatment when pregnancy is planned; implement appropriate contraception before initiation, during treatment, and for 6 months after the final dose.
    • If pregnancy occurs during treatment, discontinue Tepezza and advise the patient of potential fetal risk.
    Denial Risk

    Excessive or Nonstandard Dosing

    Coverage is at risk when the requested regimen exceeds the FDA-approved dose and schedule.

    • Approved regimen: one 10 mg/kg dose followed by up to seven 20 mg/kg infusions.
    • Infusions are administered every 3 weeks over 6 months of therapy.
    Denial Risk

    Criteria Not Met or Other Indication

    Coverage is at risk when the medical-necessity criteria are not met or Tepezza is requested for an indication other than the covered Graves' disease–associated TED criteria.

    • Requests that fail the initial-treatment or incomplete-course criteria may be denied as not medically necessary.
    • Requests for all other indications may be denied.
  6. At least one qualifying ocular finding

    • Lid retraction greater than 2 mm.
    • Moderate or severe soft-tissue involvement.
    • Proptosis greater than 3 mm above normal values for race and sex.
    • Periodic or constant diplopia.
  7. The individual is euthyroid or mildly hyperthyroid or hypothyroid before starting Tepezza therapy.Free T4 and free T3 levels within 50% of normal limits for age and gender; for individuals age 20 years or older, free T4 0.9–1.7 ng/dL and free T3 2.8–4.4 pg/mL.
  8. One clinical-rationale pathway

    • Significant proptosis or diplopia is present.
    • The individual has had an inadequate response, serious adverse effects, or a contraindication to 8 weeks of systemic corticosteroid therapy up to maximally indicated doses.